Michelle McMurry-Heath (BIO via YouTube)
October 9, 2022 11:53 PM EDTUpdated 06:10 AM
People
FDA+

BIO chief Mc­Mur­ry-Heath on leave as storm clouds gath­er over group’s di­rec­tion, leg­isla­tive set­back

John Carroll

Editor & Founder

Af­ter a short, rocky two-year tenure high­light­ed by an event-killing pan­dem­ic, cut­backs and new pric­ing leg­is­la­tion wide­ly viewed in biotech as a calami­ty, BIO CEO …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times